-
公开(公告)号：US20120329781A1
公开(公告)日：2012-12-27
申请号：US13597462
申请日：2012-08-29
IPC分类号： A61K31/195 , A61K31/4245 , A61K31/41 , A61K31/20 , A61K31/4525 , A61K31/343 , A61K31/451 , A61K31/496 , A61K31/445 , A61K31/38 , A61K31/4465 , A61K31/5375 , A61K31/55 , A61K31/415 , A61K31/381 , A61P29/00 , A61P25/00 , A61K31/197
CPC分类号： A61K31/5375 , A61K31/135 , A61K31/136 , A61K31/137 , A61K31/165 , A61K31/195 , A61K31/196 , A61K31/197 , A61K31/381 , A61K45/06 , A61K2300/00
摘要： The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.
摘要翻译： 本发明涉及α-2-δ配体和双重5-羟色胺 - 去甲肾上腺素再吸收抑制剂（DSNRI）或选择性5-羟色胺再吸收抑制剂（SSRI）和其中一种或两种的组合，特别是协同组合 选择性去甲肾上腺素再摄取抑制剂（SNRI）及其药学上可接受的盐，其药物组合物及其在治疗疼痛，特别是神经性疼痛中的用途。
-
公开(公告)号：US20100081718A1
公开(公告)日：2010-04-01
申请号：US12629516
申请日：2009-12-02
IPC分类号： A61K31/195 , A61P43/00
CPC分类号： A61K31/5375 , A61K31/135 , A61K31/136 , A61K31/137 , A61K31/165 , A61K31/195 , A61K31/196 , A61K31/197 , A61K31/381 , A61K45/06 , A61K2300/00
摘要： The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salths thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.
摘要翻译： 本发明涉及α-2-δ配体和双重5-羟色胺 - 去甲肾上腺素再吸收抑制剂（DSNRI）或选择性5-羟色胺再吸收抑制剂（SSRI）和其中一种或两种的组合，特别是协同组合 选择性去甲肾上腺素再吸收抑制剂（SNRI）及其药学上可接受的盐，其药物组合物及其在治疗疼痛，特别是神经性疼痛中的用途。
-
公开(公告)号：US20090036487A1
公开(公告)日：2009-02-05
申请号：US12247447
申请日：2008-10-08
IPC分类号： A61K31/4353 , A61K31/195
CPC分类号： A61K45/06 , A61K31/196 , A61K31/197 , A61K31/27 , A61K31/407 , A61K31/445 , A61K31/454 , A61K31/473 , A61K31/55 , A61K31/662 , A61K2300/00
摘要： The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred AChE inhibitors are donepezil (Aricept®), tacrine (Cognex®), rivastigmine (Exelon®), physostgmine (Synapton®), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil.
摘要翻译： 本发明涉及用于治疗的α-2-δ配体和AChE抑制剂的组合，特别是用于治疗疼痛，特别是神经性疼痛。 特别优选的α-2-δ配体是加巴喷丁和普瑞巴林。 特别优选的AChE抑制剂是多奈哌齐（Aricept），他克林（R）），利凡斯的明（Exelon），毒蜥塞斯汀（Synapon），加兰他敏（Reminyl），偏头痛（Promem），新斯的明（Prostigmin ）和icopezil。
-
4.发明授权Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor 失效α-2-δ配体和cGMP磷酸二酯5抑制剂的协同组合公开(公告)号：US07419981B2
公开(公告)日：2008-09-02
申请号：US10771183
申请日：2004-02-03
IPC分类号： A61K31/519 , A61K31/53 , A61K31/498 , A61K31/195 , C07D471/04 , C07D471/22 , C07D241/38 , C07D229/28
CPC分类号： A61K31/195 , A61K31/197 , A61K31/41 , A61K31/4985 , A61K31/519 , A61K31/522 , A61K31/53 , A61K2300/00
摘要： The instant invention relates to a combination of an alpha-2-delta ligand and a PDEV inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. A particularly preferred PDEV inhibitors is sildenafil.
摘要翻译： 本发明涉及用于治疗的α-2-δ配体和PDEV抑制剂的组合，特别是用于治疗疼痛，特别是神经性疼痛。 特别优选的α-2-δ配体是加巴喷丁和普瑞巴林。 特别优选的PDEV抑制剂是西地那非。
-
公开(公告)号：US20090170897A1
公开(公告)日：2009-07-02
申请号：US11568166
申请日：2005-04-08
CPC分类号： A61K31/4709 , A61K31/4706
摘要： The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.
摘要翻译： 本发明涉及CRTH2受体拮抗剂在制备用于治疗神经性疼痛的药物中的用途以及使用CRTH2受体拮抗剂治疗神经性疼痛的方法。
-
公开(公告)号：US20090214426A1
公开(公告)日：2009-08-27
申请号：US11569334
申请日：2005-05-10
申请人： Laura Corradini , Mark John Field
发明人： Laura Corradini , Mark John Field
IPC分类号： A61K49/00
CPC分类号： G01N33/5088
摘要： The present invention is related to the field of pharmacy. The present invention more particularly discloses a method of determining the emotional, sensory, physiological, social and cognitive effects of a pain condition in a non human animal and further discloses a method for preclinically identifying pharmaceutical therapeutics which improve the emotional, sensory, physiological, social and cognitive effects associated with a pain condition in a non human animal.
摘要翻译： 本发明涉及药学领域。 本发明更具体地公开了一种确定非人类动物中疼痛状况的情绪，感觉，生理，社会和认知效应的方法，并且还公开了一种用于临床前鉴定药物治疗剂的方法，其改善了情绪，感觉，生理，社会 以及与非人类动物中的疼痛状况相关的认知效应。
-
公开(公告)号：US20080294071A1
公开(公告)日：2008-11-27
申请号：US11569328
申请日：2005-05-10
申请人： Laura Corradini , Mark John Field
发明人： Laura Corradini , Mark John Field
IPC分类号： A61B5/11
CPC分类号： A61B5/1038 , A61B5/1105 , A61B5/16 , A61B5/4023 , A61B2503/40 , A61B2503/42
摘要： An assay for the assessment of drug side effects particularly the side effect of dizziness comprising the steps of: providing a first control animal located on abeam; inducing the control animal to traverse the beam; recording the number of footslips made by the animal during the traversal; providing a second test animal located on the beam or duplicate beam; inducing the test animal to traverse the beam; recording the number of footslips made by the animal during the traversal and determining whether there is an increase, decrease or no change in the number of footslips made by the test animal in comparison to the control animal.
摘要翻译： 用于评估药物副作用的测定，特别是眩晕的副作用，包括以下步骤：提供位于腹膜上的第一对照动物; 诱导对照动物穿过光束; 记录动物在穿行过程中产生的滑坡数; 提供位于梁或重复梁上的第二测试动物; 诱导测试动物穿过梁; 记录动物在穿越过程中产生的滑坡数，并确定与对照动物相比，测试动物产生的滑坡数量是否增加，减少或没有变化。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.042 秒)
